---
document_datetime: 2025-11-23 13:11:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/optimark.html
document_name: optimark.html
version: success
processing_time: 0.1210699
conversion_datetime: 2025-12-28 08:24:46.574188
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Optimark

[RSS](/en/individual-human-medicine.xml/66500)

##### Withdrawn

This medicine's authorisation has been withdrawn

gadoversetamide

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Optimark](#news-on)
- [More information on Optimark](#more-information-on-optimark-1345)
- [More information on Optimark](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Optimark (gadoversetamide) expired on 25 July 2017 following the decision of the marketing authorisation holder, Guerbet, not to apply for a renewal of the marketing authorisation.

Optimark was granted marketing authorisation in the European Union (EU) on 23 July 2007 for use with magnetic resonance imaging (MRI) of the central nervous system and the liver. The marketing authorisation was valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2012.

The European Public Assessment Report (EPAR) for Optimark is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Optimark : EPAR - Summary for the public

English (EN) (555.62 KB - PDF)

**First published:** 02/08/2007

**Last updated:** 16/06/2016

[View](/en/documents/overview/optimark-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-593)

български (BG) (601.15 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/bg/documents/overview/optimark-epar-summary-public_bg.pdf)

español (ES) (519.27 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/es/documents/overview/optimark-epar-summary-public_es.pdf)

čeština (CS) (582.11 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/cs/documents/overview/optimark-epar-summary-public_cs.pdf)

dansk (DA) (518.11 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/da/documents/overview/optimark-epar-summary-public_da.pdf)

Deutsch (DE) (520.06 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/de/documents/overview/optimark-epar-summary-public_de.pdf)

eesti keel (ET) (517.61 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/et/documents/overview/optimark-epar-summary-public_et.pdf)

ελληνικά (EL) (113.66 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/el/documents/overview/optimark-epar-summary-public_el.pdf)

français (FR) (519.79 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/fr/documents/overview/optimark-epar-summary-public_fr.pdf)

hrvatski (HR) (540.94 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/hr/documents/overview/optimark-epar-summary-public_hr.pdf)

italiano (IT) (518.64 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/it/documents/overview/optimark-epar-summary-public_it.pdf)

latviešu valoda (LV) (581.87 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/lv/documents/overview/optimark-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (543.05 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/lt/documents/overview/optimark-epar-summary-public_lt.pdf)

magyar (HU) (575.18 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/hu/documents/overview/optimark-epar-summary-public_hu.pdf)

Malti (MT) (1.01 MB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/mt/documents/overview/optimark-epar-summary-public_mt.pdf)

Nederlands (NL) (519.11 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/nl/documents/overview/optimark-epar-summary-public_nl.pdf)

polski (PL) (581.08 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/pl/documents/overview/optimark-epar-summary-public_pl.pdf)

português (PT) (519.39 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/pt/documents/overview/optimark-epar-summary-public_pt.pdf)

română (RO) (542.79 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/ro/documents/overview/optimark-epar-summary-public_ro.pdf)

slovenčina (SK) (582.33 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/sk/documents/overview/optimark-epar-summary-public_sk.pdf)

slovenščina (SL) (575.26 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/sl/documents/overview/optimark-epar-summary-public_sl.pdf)

Suomi (FI) (518.16 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/fi/documents/overview/optimark-epar-summary-public_fi.pdf)

svenska (SV) (82.2 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

16/06/2016

[View](/sv/documents/overview/optimark-epar-summary-public_sv.pdf)

## Product information

Optimark : EPAR - Product Information

English (EN) (1.2 MB - PDF)

**First published:** 23/04/2009

**Last updated:** 08/05/2017

[View](/en/documents/product-information/optimark-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-799)

български (BG) (2.06 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/bg/documents/product-information/optimark-epar-product-information_bg.pdf)

español (ES) (985.8 KB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/es/documents/product-information/optimark-epar-product-information_es.pdf)

čeština (CS) (1.71 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/cs/documents/product-information/optimark-epar-product-information_cs.pdf)

dansk (DA) (1005.25 KB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/da/documents/product-information/optimark-epar-product-information_da.pdf)

Deutsch (DE) (1.01 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/de/documents/product-information/optimark-epar-product-information_de.pdf)

eesti keel (ET) (1006.71 KB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/et/documents/product-information/optimark-epar-product-information_et.pdf)

ελληνικά (EL) (2.13 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/el/documents/product-information/optimark-epar-product-information_el.pdf)

français (FR) (1018.41 KB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/fr/documents/product-information/optimark-epar-product-information_fr.pdf)

hrvatski (HR) (1.09 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/hr/documents/product-information/optimark-epar-product-information_hr.pdf)

íslenska (IS) (1.23 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/is/documents/product-information/optimark-epar-product-information_is.pdf)

italiano (IT) (1.01 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/it/documents/product-information/optimark-epar-product-information_it.pdf)

latviešu valoda (LV) (1.75 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/lv/documents/product-information/optimark-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.17 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/lt/documents/product-information/optimark-epar-product-information_lt.pdf)

magyar (HU) (1.71 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/hu/documents/product-information/optimark-epar-product-information_hu.pdf)

Malti (MT) (1.8 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/mt/documents/product-information/optimark-epar-product-information_mt.pdf)

Nederlands (NL) (1012.41 KB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/nl/documents/product-information/optimark-epar-product-information_nl.pdf)

norsk (NO) (1.03 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/no/documents/product-information/optimark-epar-product-information_no.pdf)

polski (PL) (1.74 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/pl/documents/product-information/optimark-epar-product-information_pl.pdf)

português (PT) (1009.87 KB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/pt/documents/product-information/optimark-epar-product-information_pt.pdf)

română (RO) (1.09 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/ro/documents/product-information/optimark-epar-product-information_ro.pdf)

slovenčina (SK) (1.69 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/sk/documents/product-information/optimark-epar-product-information_sk.pdf)

slovenščina (SL) (1.64 MB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/sl/documents/product-information/optimark-epar-product-information_sl.pdf)

Suomi (FI) (1007.02 KB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/fi/documents/product-information/optimark-epar-product-information_fi.pdf)

svenska (SV) (497.12 KB - PDF)

**First published:**

23/04/2009

**Last updated:**

08/05/2017

[View](/sv/documents/product-information/optimark-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0037 11/04/2017

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Optimark : EPAR - All Authorised presentations

English (EN) (477.19 KB - PDF)

**First published:** 02/08/2007

**Last updated:** 02/08/2007

[View](/en/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-50)

български (BG) (527.81 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/bg/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_bg.pdf)

español (ES) (463.1 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/es/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_es.pdf)

čeština (CS) (512.46 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/cs/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (463.8 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/da/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (463.6 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/de/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (480.08 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/et/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (522.2 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/el/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_el.pdf)

français (FR) (463.83 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/fr/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (462.96 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/it/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (517.54 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/lv/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (504.23 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/lt/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (509.05 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/hu/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (961.67 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/mt/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (463.9 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/nl/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_nl.pdf)

polski (PL) (518.16 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/pl/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_pl.pdf)

português (PT) (463.3 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/pt/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_pt.pdf)

română (RO) (507.13 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/ro/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (516.38 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/sk/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (475.53 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/sl/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (463.28 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/fi/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (22.66 KB - PDF)

**First published:**

02/08/2007

**Last updated:**

02/08/2007

[View](/sv/documents/all-authorised-presentations/optimark-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Optimark Active substance gadoversetamide International non-proprietary name (INN) or common name gadoversetamide Therapeutic area (MeSH) Magnetic Resonance Imaging Anatomical therapeutic chemical (ATC) code V08CA06

### Pharmacotherapeutic group

Contrast media

### Therapeutic indication

This medicinal product is for diagnostic use only.

Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver. It provides contrast enhancement and facilitates visualisation and helps with the characterisation of focal lesions and abnormal structures in the CNS and liver in patients with known or highly suspected pathology.

## Authorisation details

EMA product number EMEA/H/C/000745 Marketing authorisation holder

Mallinckrodt Deutschland GmbH

Guerbet

Marketing authorisation issued 23/07/2007 Withdrawal of marketing authorisation 25/07/2017 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Optimark : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (627.37 KB - PDF)

**First published:** 23/04/2009

**Last updated:** 08/05/2017

[View](/en/documents/procedural-steps-after/optimark-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Optimark-H-C-PSUSA-00001508/201501 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/696878/2015

English (EN) (529.98 KB - PDF)

**First published:** 21/01/2016

**Last updated:** 21/01/2016

[View](/en/documents/scientific-conclusion/optimark-h-c-psusa-00001508201501-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Optimark-H-C-745-A20-0004 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/452192/2010

English (EN) (661.61 KB - PDF)

**First published:** 25/11/2010

**Last updated:** 25/11/2010

[View](/en/documents/variation-report/optimark-h-c-745-a20-0004-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Optimark : EPAR - Scientific Discussion

English (EN) (1.92 MB - PDF)

**First published:** 30/05/2008

**Last updated:** 30/05/2008

[View](/en/documents/scientific-discussion/optimark-epar-scientific-discussion_en.pdf)

Optimark : EPAR - Procedural steps taken before authorisation

English (EN) (486.98 KB - PDF)

**First published:** 02/08/2007

**Last updated:** 02/08/2007

[View](/en/documents/procedural-steps/optimark-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Optimark

[EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans](/en/news/emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans) 21/07/2017

[PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations](/en/news/prac-concludes-assessment-gadolinium-agents-used-body-scans-recommends-regulatory-actions-including-suspension-some-marketing-authorisations) 10/03/2017

#### More information on Optimark

Questions and answers on the review of gadolinium-containing contrast agents

Adopted

Reference Number: EMEA/727399/2009

English (EN) (48.93 KB - PDF)

**First published:** 21/11/2009

**Last updated:** 02/09/2010

[View](/en/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_en.pdf)

[Other languages (21)](#file-language-dropdown-280)

български (BG) (242.44 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/bg/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_bg.pdf)

español (ES) (113.18 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/es/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_es.pdf)

čeština (CS) (192.16 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/cs/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_cs.pdf)

dansk (DA) (49.95 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/da/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_da.pdf)

Deutsch (DE) (50.93 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/de/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_de.pdf)

eesti keel (ET) (49.65 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/et/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_et.pdf)

ελληνικά (EL) (237.73 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/el/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_el.pdf)

français (FR) (51.25 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/fr/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_fr.pdf)

italiano (IT) (50.72 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/it/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_it.pdf)

latviešu valoda (LV) (193.87 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/lv/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_lv.pdf)

lietuvių kalba (LT) (191.27 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/lt/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_lt.pdf)

magyar (HU) (96.49 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/hu/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_hu.pdf)

Malti (MT) (220.89 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/mt/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_mt.pdf)

Nederlands (NL) (50.88 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/nl/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_nl.pdf)

polski (PL) (136.04 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/pl/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_pl.pdf)

português (PT) (111.38 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/pt/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_pt.pdf)

română (RO) (189.91 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/ro/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_ro.pdf)

slovenčina (SK) (189.71 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/sk/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_sk.pdf)

slovenščina (SL) (184.89 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/sl/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_sl.pdf)

Suomi (FI) (48.64 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/fi/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_fi.pdf)

svenska (SV) (49.62 KB - PDF)

**First published:**

21/11/2009

**Last updated:**

02/09/2010

[View](/sv/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_sv.pdf)

#### More information on Optimark

- [Gadolinium-containing contrast agents - referral](/en/medicines/human/referrals/gadolinium-containing-contrast-agents)

**This page was last updated on** 11/12/2017

## Share this page

[Back to top](#main-content)